#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neuroendocrine carcinoma metastatic Polymyositis Head and neck cancer Hodgkin's disease refractory Neurotrophic keratopathy Follicle centre lymphoma follicular grade I, II – III Measles Ovarian cancer stage III Primitive neuroectodermal tumour Small cell lung cancer recurrent Mastocytosis Osteomyelitis Thalassaemia Anal cancer Malignant neoplasm of choroid More trials…

    Learn about Rare Diseases

    Myxofibrosarcoma – Trials in Disease Krabbe’s disease – Treatment Stevens-Johnson syndrome – Life with Disease Erdheim-Chester disease – Trials in Disease Atypical haemolytic uraemic syndrome – Treatment Angiosarcoma non-metastatic – Life with Disease Hairy cell leukaemia – Treatment Anaplastic thyroid cancer – Trials in Disease Leiomyosarcoma metastatic – Diagnostics Tuberous sclerosis complex More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    L-LEUCINE IADADEMSTAT SARACATINIB Cx-039776 Omp12 Florbetapir (18F) Ifezuntirgene Inilparvovec Zidovudine Insulin Lispro Rezpegaldesleukin Zolbetuximab Dexketoprofen Trometamol Perflubutane Sonelokimab Evg321 Tng462 Calcium Chloride Hexahydrate Ketoprofen Cefotaxime Darunavir More therapies…

    Learn about Your Condition

    Alcohol abuse Cardiac arrest Pathogen resistance Sinus rhythm Thymic carcinoma Extra-osseous Ewing's sarcoma Chronic fatigue syndrome Injection site pain Cachexia Chronic coronary syndrome Prostate cancer metastatic Red blood cell abnormality Pyelonephritis acute Medulloblastoma Hypertrophic scar More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • A Study of Cagrilintide and Semaglutide for Weight Loss in People with Type 2 Diabetes and Overweight or Obesity

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    • Obesity
    • Overweight
    Investigated Drugs:
    • Cagrilintide
    • Semaglutide
    Austria Germany Hungary Ireland Poland

  • Study of AMG 732 injection compared to placebo in patients with moderate to severe thyroid eye disease

    Not recruiting

    2 1
    Investigated Drugs:
    • AMG 732
    France Germany Greece Italy Poland Spain

  • Long-term study of dabrafenib and trametinib in children and adolescents with cancers that have V600 mutation

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Dabrafenib Mesylate
    • Trametinib
    • Trametinib Dimethyl Sulfoxide
    Belgium Czechia Denmark Finland France Germany +4

  • Study of cagrilintide and semaglutide combination versus placebo in people with type 2 diabetes and painful diabetic peripheral neuropathy

    Not recruiting

    2 1
    Investigated Diseases:
    • Diabetic neuropathy
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Cagrilintide
    • Semaglutide
    Denmark France Norway Spain

  • Study of BMN 351 given by intravenous infusion to evaluate safety and tolerability in patients with Duchenne Muscular Dystrophy

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Duchenne muscular dystrophy
    Italy The Netherlands Spain

  • Study of luxdegalutamide and abiraterone combination in adult men with metastatic hormone-sensitive prostate cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • LUXDEGALUTAMIDE
    • Relugolix
    • Abiraterone
    Czechia France Germany Italy The Netherlands Poland +1
Previous Page
1 … 1,632 1,633 1,634 1,635 1,636 … 1,645
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!